Harrow price to free cash flow HROW

Market value divided by free cash flow over the last twelve months, since 2017.

Today, Oct 23, 2026: 213×
9-year median: 131×
Against its 9-year history: 69th; percentile: 0 is its lowest day, 100 its highest
9-year range: 15.7× to 494×
Peer median: 8.1×

Harrow's price to free cash flow is 213× as of Oct 23, 2026.

That is above its 9-year median of 131×, higher than on 69% of days in the last 9 years.

Over that time it ranged from 15.7× in Feb 2018 to 494× in Nov 2025.

The median for 10 large drugmakers of a similar size is 8.1×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	213×	28.8×	306×
2025	112×	87.0×	494×
2024	393×	93.0×	491×
2023	230×	189×	247×
2022	195×	43.4×	283×
2021	54.4×	26.8×	153×
2020	375×	267×	384×
2019	n/m a value too high to mean anything
2018	18.6×	15.7×	18.6×
2017	16.7×	16.1×	18.4×

Against its peers

Companies in Drug Manufacturers - General nearest Harrow's size, closest first, today.

Company	Price to free cash flow
HROWHarrow	213×
AMPHAmphastar Pharmaceuticals	7.0×
OMEROmeros	n/m
ABUSArbutus Biopharma	n/m
PCRXPacira BioSciences	8.1×
ANABAnaptysbio	n/m
COLLCollegium Pharmaceutical	2.3×
PAHCPhibro Animal Health	160×
ANIPANI Pharmaceuticals	9.6×
CRMDCorMedix	2.4×
ZVRAZevra Therapeutics	17.9×
Peer median	8.1×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Harrow

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.